MarginsXMarginsX
Home › Markets › Health Care › MGNX

MacroGenics Inc. (MGNX)

MGNX trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$2.17
-1.36% on the day
Market cap
$138.7M
Micro cap
Revenue · 2025
$149.5M
-0.3% on 2024
Net income · 2025
-$74.6M
-49.9% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1125345/000112534526000017/0001125345-26-000017-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerMGNX on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO year2013
SEC CIK0001125345
SEC industry codePharmaceutical Preparations
Incorporated inDE

Financials · 2025

LineValue
Revenue$149.5M
Net income-$74.6M
Operating income-$72.8M
Net margin-49.9%
Operating margin-48.7%
Revenue growth-0.3%
Cash$57.2M
Total assets$256.8M
P/E (computed)Net income was not positive
P/S (computed)0.9×

Warning signs

Cash runway
14.8 months
$49.0M cash at September 30, 2026
Share count, 1 year
+1.0%
2025-11-07 to 2026-11-06 · +3.0% over 3 years
Going-concern doubt
No
10-Q filed November 12, 2026
Insider net buying, 12 months
-$129K
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-12
Cash and burn$49.0M cash; operating cash flow -$10.0M a quarter.Report 2026-09-30
Shares outstanding63,908,946 (2026-11-06); 63,258,532 a year earlier; 62,029,447 three years earlier.Cover page 2026-11-06
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorErnst & Young LLP, Tysons, Virginia, United StatesPCAOB Form AP 2026-03-24
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $129K on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$18.7M-$20.1M-$6.3M$49.0MNo debt tags$154.9M10-Q 2026-11-12
Q2 2026
2026-06-30
$32.8M$19.5M-$40.7M$113.9MNo debt tags$189.2M10-Q 2026-08-14
Q1 2026
2026-03-31
$20.8M-$36.8M-$35.8M$66.5MNo debt tags$163.2M10-Q 2026-05-13
Q4 2025
2025-12-31
$82.6M-$14.2M$43.0M$57.2MNo debt tags$155.6M10-K 2026-03-09
Q3 2025
2025-09-30
$53.0M$16.8M-$30.2M$80.1MNo debt tags$92.4M10-Q 2026-11-12
Q2 2025
2025-06-30
$6.9M-$36.3M-$47.0M$130.7MNo debt tags$150.1M10-Q 2026-08-14
Q1 2025
2025-03-31
$13.2M-$41.0M-$46.9M$145.6MNo debt tags$154.1M10-Q 2026-05-13
Q4 2024
2024-12-31
$19.4M-$15.4M-$38.4M$182.8MNo debt tags$150.0M10-K 2026-03-09

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering documentS-32023-11-06
Latest annual report10-K2026-03-09
Latest quarterly / interim10-Q2026-11-12
Latest current report8-K2026-11-13
Latest proxyDEFA14A2026-04-22

Source: SEC EDGAR submissions feed, 948 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-5.6%
1 month-35.7%
3 months-46.1%
Year to date+36.6%
1 year+37.5%
From 52-week high-54.7%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
RNAAtrium Therapeutics Inc.$6.43-14.38%$138.7M
MSLESatellos Bioscience Inc.$6.47-2.34%$137.3M
SIONSionna Therapeutics Inc.$3.12-6.31%$141.1M
MENSJyong Biotech Ltd.$1.77+0.57%$134.6M
NTHINeOnc Technologies Holdings Inc.$4.54-7.54%$131.0M
CNTNCanton Strategic Holdings Inc.$1.64-4.09%$130.7M
VRXAVeraxa Biotech AG$1.04-5.86%$147.8M
ABEOAbeona Therapeutics Inc.$2.60+7.44%$148.6M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier